Tyra Bioscience Shows Promise with TYRA-300 Results
Company Announcements

Tyra Bioscience Shows Promise with TYRA-300 Results

Tyra Bioscience ( (TYRA) ) has provided an announcement.

Tyra Biosciences announced promising interim clinical results for TYRA-300 in metastatic urothelial cancer, with significant anti-tumor activity observed in patients receiving doses of 90 mg or higher. The treatment demonstrated a 100% disease control rate and favorable safety profile, showing potential as a novel therapy for FGFR3+ cancer patients. Investors can tune into a webcast on October 25, 2024, for more detailed insights into these findings.

For detailed information about TYRA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyTyra Biosciences price target lowered to $29 from $31 at BofA
TheFlyTyra Biosciences price target lowered to $30 from $32 at H.C. Wainwright
TipRanks Auto-Generated NewsdeskTyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App